

June 29, 2020

To, BSE Limited The Corporate Relationship Dept. P.J. Towers, Dalal Street, Mumbai – 400 001

BSE Company Code: 500214

Dear Sir/ Madam,

Sub: Submission of Analyst / Investor Presentation

Pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed presentation being made to Analyst / Institutional Investor to discuss the Financial performance of the Company for the year ended March 31, 2020.

The aforesaid information is also disclosed on website of the company i.e. www.ionindia.com

Kindly take the information on record.

Thanking You,

Yours faithfully, For Ion Exchange (India) Limited

MILLIND DATTATRAY DATTATRAY A PURANIK A PURANIK

Milind Puranik Company Secretary

ION EXCHANGE (INDIA) LTD. | CIN: L74999MH1964PLC014258

Regd. Office: Ion House, Dr. E. Moses Road, Mahalaxmi, Mumbai - 400 011, India. Board: +91 22 6231 2000 | Fax: +91 22 2493 8737 | E-mail: ieil@ionexchange.co.in | Web: www.ionindia.com



Executive Summary

FY20: Operating Income* INR 14,798 Mn

> FY20: Operating EBITDA* INR 1,346 Mn

FY20: PAT* INR 940 Mn

*Consolidated

OVERVIEW

- Ion Exchange (India) Ltd (Ion Exchange), formed in 1964, is a pioneer in water, waste water treatment & environment solutions and caters to various industries, homes & communities.
- Headquartered in Mumbai, the company has six manufacturing & assembly facilities across India, and one each in Bangladesh and UAE. It also has presence across other key geographies.
- Installation: 1 lakh globally; 500+ in core sectors.

BUSINESS & REVENUE (%) MIX -CONSOLIDATED

- Engineering (61%) Provides comprehensive and integrated services and solutions in water & waste water treatment including Sea Water desalination, Recycle and Zero liquid discharge plants to diverse industries.
- Chemicals (31%) Provides a comprehensive range of resins, speciality chemicals and customized chemical treatment programmes for water, non-water and specialty applications.
- Consumer Products (8%) Caters to individuals, hotels, spas, educational institutions, hospitals, laboratories, railway and defence establishments providing safe drinking water and a clean environment.

MARQUEE CLIENTS

- Industrial NTPC, NPC, Reliance, IOCL, JSW, CPCL, L&T, Essar group, IRCTC, BHEL, Tata Group.
- Institutional Leela, Military Engineering Services, Taj Hotels, Holiday Inn, Hyatt Regency, Oberoi Hotels, Apollo Hospitals, Escorts Heart Institute, DLF, Puravankar.
- International Cargill, Technip France, Unilever Group, Jurong, Thyssenkrupp (Uhde), Jacobs, Kawasaki, Mitsubishi, PDO Oman, Emirates Steel, IKPP Indonesia.

Company Overview

- Ion Exchange was originally formed as a subsidiary of Permutit, UK in 1964. It became a wholly owned Indian company in 1985. The company is currently in its 56th Year of operations.
- The company has expanded its footprints globally and possesses a diversified product range. It offers one stop water and non-water treatment solutions catering to diverse segments like infrastructure, industry, institutions, municipal, homes and communities, urban and rural.
- The company offers a wide range of solutions across the water cycle from pretreatment to process water treatment, waste water treatment, recycle, zero liquid discharge, sewage treatment, packaged drinking water, sea water desalination etc.
- The company is also engaged in manufacturing ion exchange resins, speciality chemicals for water and waste water treatment as well as non-water applications.
- It has two facilities for in-house R&D and two applications and testing centers.
- The company has over 50 patents to their credit and 100+ products commercialized.
- The company has a global presence apart from presence in major cities in India with sales & service centers and dealer network of more than 100.
- The company exports to Africa, Japan, Middle East, Russia, South East Asia, Europe, UK, USA, Canada and neighbouring countries.

REVENUE BREAK UP FY20*





FY20 / Q4-FY20 FINANCIAL HIGHLIGHTS

- **Q4-FY20** Performance (Standalone):
 - Operating Income: INR 3,279 Mn
 - Operating EBITDA: INR 327 Mn
 - Operating EBITDA Margins: 9.97%
 - Net Profit: INR 289 Mn
 - PAT Margins: 8.81%
 - Diluted EPS: INR 23.49 per share
- **FY20** Performance (Standalone):
 - Operating Income: INR 14,072 Mn
 - Operating EBITDA: INR 1,210 Mn
 - Operating EBITDA Margins: 8.60%
 - Net Profit: INR 991 Mn
 - PAT Margins: 7.04%
 - Diluted EPS: INR 81.85 per share

- **Q4-FY20** Performance (Consolidated):
 - Operating Income: INR 3,511 Mn
 - Operating EBITDA: INR 393 Mn
 - Operating EBITDA Margins: 11.19%
 - Net Profit: INR 287 Mn
 - PAT Margins: 8.17%
 - Diluted EPS: INR 24.22 per share
- **FY20** Performance (Consolidated):
 - Operating Income: INR 14,798 Mn
 - Operating EBITDA: INR 1,346 Mn
 - Operating EBITDA Margins: 9.10%
 - Net Profit: INR 940 Mn
 - PAT Margins: 6.35%
 - Diluted EPS: INR 80.55 per share

FY20 / Q4-FY20 OPERATIONAL HIGHLIGHTS

Business Operations

- > Operations of the Company were affected in Q4-FY20 due to COVID 19 pandemic and the resultant lockdowns in several geographies including India.
- > This resulted in deferral of despatches in all the three segments thereby impacting the sales and margins.
- > Currently with the phase wise lifting of the lockdown, all our manufacturing operations and offices at most of the locations are functional.
- > We have invoked FORCE MAJEURE clause for all our major projects where the Company foresees contractual delays due to the lockdown.

Engineering

- Revenue recognition for the Sri Lanka project in the quarter was affected due to the COVID 19 lockdown impact. Post receipt of necessary permissions from the Sri Lanka Govt, we have recently resumed our supplies and civil works.
- Whilst the Engineering order book remains healthy, the order intake for the quarter was muted due to the general economy slowdown and the delay in order finalisations caused by the lockdown.

Chemicals

Margins improved due to operational efficiencies resulting from the capacity increases coupled with change in product mix due to seasonality of certain product lines.

Consumer

> Adverse impact of the COVID 19 lockdown significantly affected the volumes thereby resulting in lower recovery of fixed costs.

Q4-FY20 STANDALONE INCOME STATEMENT (IND-AS)

INCOME STATEMENT (INR MN)		Q4-FY20	Q4-FY19	Y-o-Y	Q3-FY20	Q-o-Q
Operating Income		3,279	4,181	(21.6)%	3,781	(13.3)%
Expenses		2,952	3,677	(19.7)%	3,413	(13.5)%
Operating EBITDA		327	504	(35.1)%	368	(11.1)%
Operating EBITDA Margins (%)		9.97%	12.05%	(208) Bps	9.73%	24 Bps
Depreciation		61	47	29.8%	55	10.9%
Finance Cost		32	42	(23.8)%	35	(8.6)%
Other Income		155	48	NA	104	49.0%
РВТ		389	463	(16.0)%	382	1.8%
Тах		100	155	(35.5)%	104	(3.8)%
Profit After Tax		289	308	(6.2)%	278	4.0%
PAT Margins (%)		8.81%	7.37%	144 Bps	7.35%	146 Bps
Other Comprehensive Income		(5)	(4)	NA	(2)	NA
Total Comprehensive Income		284	304	(6.6)%	276	2.9%
Diluted EPS (INR)		23.49#	25.68*	(8.5)%	22.87 [#]	2.7%
*Earnings per equity share includes impact of equity shares held by IEI #Earnings per equity share includes impact of equity shares held by						shares held bv

*Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. No. of Shares- 26,62,914 #Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. No. of Shares- 23,68,939

SEGMENTAL BREAKUP- QUARTERLY STANDALONE



STANDALONE INCOME STATEMENT (IND-AS)

INCOME STATEMENT (INR MN)	FY20	FY19	Y-o-Y	
Operating Income	14,072	11,023	27.7%	
Expenses	12,862	10,110	27.2%	
Operating EBITDA	1,210	913	32.5%	
Operating EBITDA Margins (%)	8.60%	8.28%	32 Bps	
Depreciation	221	181	22.1%	
Finance Cost	132	162	(18.5)%	
Other Income	485	441	10.0%	
РВТ	1,342	1,011	32.7%	
Tax	351	345	1.7%	
Profit After Tax	991	666	48.8%	
PAT Margins (%)	7.04%	6.04%	100 Bps	
Other Comprehensive Income	(9)	(5)	NA	
Total Comprehensive Income	982	661	48.6%	
Diluted EPS (INR)	81.85 [#]	55.47*	47.6%	
*Earnings per equity share includes impact of equity shares held by IEI #Earnings per equity share includes impact of equity shares held				

Shareholding (Staff Welfare) Trusts. No. of Shares- 26,62,914 #Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. No. of Shares- 23,68,939

SEGMENTAL BREAKUP- STANDALONE



STANDALONE BALANCE SHEET (As Per IND-AS)

PARTICULARS (INR MN)	FY20	FY19	PARTICULARS (INR MN)	FY20	FY19
EQUITIES & LIABILITIES			ASSETS		
Equity			Non-Current Assets		
(A) Equity Share Capital	147	147	(A) Property, Plant and Equipment	1,623	1,425
(B) Other Equity	4,668	3,597	(B) Capital Work-in-progress	179	123
Total Equity	4,815	3,744	(C) Right-of-Use Assets	67	-
Non-Current Liabilities			(D) Other Intangible Assets	16	14
(A) Financial Liabilities			(E) Financial Assets		
(i) Borrowings	271	261	(i) Investments	620	607
(ii) Lease Liabilities	17	-	(ii) Trade Receivables	29	36
(iii) Other financial Liabilities	81	81	(iii) Loans	420	403
(B) Provisions	140	118	(F) Other Non-Current Assets	53	63
(C) Deferred Tax Liabilities (Net)	-	11	(G) Deferred Tax Assets	6	-
(D) Liabilities for Non-Current Tax (Net)	19	15	Total Non – Current Assets	3,013	2,671
Total Non – Current Liabilities	528	486	Current Assets		
Current Liabilities			(A) Inventories	1,180	1,092
(A) Financial Liabilities			(B) Financial Assets		
(i) Borrowings	640	434	(i) Investments	1	4
(ii) Lease Liabilities	15	-	(ii) Trade Receivables	5,137	4,276
(iii) Trade Payables	4,570	3,948	(iii) Cash & Cash Equivalents	846	360
(iv) Other Financial Liabilities	475	380	(iv) Bank Balances	2,691	2,394
(B) Other Current Liabilities	3,118	2,979	(v) Loans	472	509
(C) Provisions	49	38	(vi) Other Financial Assets	224	184
(D) Liabilities for current tax (Net)	157	141	(C) Other current assets	803	660
Total Current Liabilities	9,024	7,920	Total Current Assets	11,354	9,479
GRAND TOTAL - EQUITIES & LIABILITES	14,367	12,150	GRAND TOTAL – ASSETS	14,367	12,150
					10

FINANCIALS - STANDALONE



Q4-FY20 CONSOLIDATED INCOME STATEMENT (IND-AS)

INCOME STATEMENT (INR MN)	Q4-FY20	Q4-FY19	Ү-о-Ү	Q3-FY20	Q-o-Q
Operating Income	3,511	4,318	(18.7)%	3,982	(11.8)%
Expenses	3,118	3,719	(16.2)%	3,590	(13.1)%
Operating EBITDA	393	599	(34.4)%	392	0.3%
Operating EBITDA Margins (%)	11.19%	13.87%	(268) Bps	9.84%	135 Bps
Depreciation	65	51	27.5%	59	10.2%
Finance Cost	40	49	(18.4)%	42	(4.8)%
Other Income	109	20	NA	76	43.4%
PBT	397	519	(23.5)%	367	8.2%
Share of Profit of equity accounted Investee	(4)	2	NA	3	NA
Тах	106	160	(33.8)%	107	(0.9)%
Profit After Tax	287	361	(20.5)%	263	9.1%
PAT Margins (%)	8.17%	8.36%	(19) Bps	6.60%	157 Bps
Other Comprehensive Income	13	(4)	NA	(7)	NA
Total Comprehensive Income	300	357	(16.0)%	256	17.2%
Diluted EPS (INR)	24.22#	31.17*	(22.3)%	22.50 [#]	7.6%
*Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts.	by IEI #Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts.				

No. of Shares- 26,62,914

No. of Shares- 23,68,939

SEGMENTAL BREAKUP-QUARTERLY CONSOLIDATED



CONSOLIDATED INCOME STATEMENT (As per IND-AS)

INCOME STATEMENT (INR MN)	FY20	FY19	Ү-о-Ү
Operating Income	14,798	11,623	27.3%
Expenses	13,452	10,557	27.4%
Operating EBITDA	1,346	1,066	26.3%
Operating EBITDA Margins (%)	9.10%	9.17%	(7) Bps
Depreciation	237	196	20.9%
Finance Cost	160	190	(15.8)%
Other Income	354	333	6.3%
PBT	1,303	1,013	28.6%
Share of Profit of equity accounted Investee	4	5	(20.0)%
Tax	367	359	2.2%
Profit After Tax	940	659	42.6%
PAT Margins (%)	6.35%	5.67%	68 Bps
Other Comprehensive Income	2	1	NA
Total Comprehensive Income	942	660	42.7%
EPS Diluted (INR)	80.55#	56.99*	41.3%

*Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts (No. of Shares-26,62,914) and shares held by Subsidiary companies (No. of Shares- 4,37,874)

#Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts (No. of Shares-23,68,939) and shares held by Subsidiary companies (No. of Shares- 4,37,874)

SEGMENTAL BREAKUP- CONSOLIDATED



CONSOLIDATED BALANCE SHEET (IND-AS)

PARTICULARS (INR MN)	FY20	FY19	PARTICULARS (INR MN)	FY20	FY19
EQUITIES & LIABILITIES			ASSETS		
Equity			Non-Current Assets		
(A) Equity Share Capital	142	142	(A) Property, Plant and Equipment	1,697	1,507
(B) Other Equity	3,489	2,458	(B) Capital Work-in-progress	179	123
Equity attributable to owners	3,631	2,600	(C) Right-of-Use Assets	77	-
Non Controlling Interest	20	22	(C) Other Intangible Assets	16	14
Total Equity	3,651	2,622	(D) Goodwill	86	86
			(E) Investment accounted using Equity Method	37	34
Non-Current Liabilities			(F) Financial Assets		
(A) Financial Liabilities			(i) Investments	7	7
(i) Borrowings	271	261	(ii) Trade Receivables	62	142
(ii) Lease liabilities	22	-	(iii) Loans	118	100
(iii) Other Financial Liabilities	81	81	(iv) Other Financial Assets	65	70
(B) Provisions	157	133	(G) Deferred Tax Assets (Net)	15	10
(C) Deferred Tax Liabilities (Net)	5	11	(H) Other Non-Current Assets	165	167
(D) Other Non-Current Liabilities	5	6	(I) Non-Current Tax Assets	5	5
(E) Liabilities for non-current tax (Net)	19	16	Total Non – Current Assets	2529	2,265
Total Non – Current Liabilities	560	508	Current Assets		
			(A) Inventories	1,345	1,298
Current Liabilities			(B) Financial Assets		
(A) Financial Liabilities			(i) Investments	1	4
(i) Borrowings	858	667	(ii) Trade Receivables	5,019	4,242
(ii) Lease liabilities	17	-	(iii) Cash & Cash Equivalents	1,015	452
(iii) Trade Payables	4,800	4,151	(iv) Bank Balances	2,716	2,452
(iv) Other Financial Liabilities	518	428	(v) Loans	173	91
(B) Other Current Liabilities	3,190	3,078	(vi) Other Financial Assets	237	197
(C) Provisions	57	45	(C) Current Tax Assets (Net)	15	13
(D) Liabilities for current tax (Net)	171	154	(D) Other Current Assets	772	639
Total Current Liabilities	9,611	8,523	Total Current Assets	11,293	9,388
GRAND TOTAL - EQUITIES & LIABILITES	13,822	11,653	GRAND TOTAL – ASSETS	13,822	11,653
					16

FINANCIALS - CONSOLIDATED



Market Data (Bloomberg – ION IN, Reuters – IONX.BO)





SHAREHOLDING PATTERN (AS ON 31st MARCH, 2020)



Disclaimer

Ion Exchange (India) Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Ion Exchange (India) Limited ("Company" or "IONEX"), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.



For further details please contact our Investor Relations Representatives: VALOREM ADVISORS Mr. Anuj Sonpal Tel: +91-22-49039500 Email: ion@valoremadvisors.com

THANK YOU